Best GLP-1 Providers in Alaska (2026)

See by medication

Looking for a specific GLP-1? Browse Alaska providers by drug.

About GLP-1s in Alaska

Alaska permits telehealth GLP-1 prescriptions, which is essential given the state's vast rural geography. Compounded semaglutide can be shipped statewide from licensed pharmacies.

• •Alaska's adult obesity rate is 32.7%, near the US median
• •Telehealth is critical in Alaska due to limited rural clinic access
• •Alaska Medicaid restricts GLP-1 coverage to diabetes diagnosis

Top Cities for GLP-1 Treatment in Alaska

Telehealth providers ship to all Alaska addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Alaska GLP-1 clinic directory →

GLP-1 Care Access in Alaska: The Numbers

Alaska has 79 NPI-registered in-person weight-management clinics across 11 cities — 1 with an obesity-medicine taxonomy, 19 endocrinology, and 59 bariatric — alongside 85 telehealth programs that ship to Alaska addresses. The cheapest verified ongoing compounded semaglutide price available to Alaska residents is $79/mo (tirzepatide: $104/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Alaska

In Q1 2026, Alaska Medicaid reimbursed approximately $5,305,127 across 5,385 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Alaska cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $229/mo.

For the exact criteria, drug list, and appeal process, read our Alaska Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Alaska

According to CDC data, 32.7% of Alaska adults have obesity (BMI of 30 or higher). This places Alaska at #24 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Alaska residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions